新辅助治疗后影像引导活检无残留病灶者可免乳腺癌手术的可行性试验
这项前瞻性多中心临床试验的可行性阶段,纳入新辅助系统治疗后影像学残留<2 cm的单灶cT1-2 N0-1 M0三阴性或HER2阳性乳腺癌患者,影像引导真空辅助空心针活检未见残留浸润或原位病灶者免除乳腺手术并接受放疗。
要点
- 新辅助后影像残留<2 cm的TNBC或HER2+BC患者可考虑影像引导VACB评估
- VACB无残留浸润或原位病灶者免手术并放疗,本队列未见同侧复发
- 仅为可行性阶段小样本早期数据,扩展阶段结果待报告
核心结论
- 新辅助系统治疗后标准化VACB无残留病灶的侵袭性TNBC和HER2+BC患者,免除乳腺手术并放疗可能可行。
主要发现
- 可行性队列中位随访44.3个月(范围41.3至51.3)无同侧乳腺肿瘤复发。
- 患者平均年龄60.8岁(范围51至75),新辅助前平均肿瘤大小2.4 cm(范围0.9至5.0),新辅助后0.7 cm(范围0至1.8)。
关键数值与推荐
- 可行性阶段主要终点为6个月同侧乳腺肿瘤复发,可行性阶段出现任何复发即终止试验。
- VACB未发现残留浸润或原位病灶时免除乳腺手术并给予放疗。
临床怎么用
- 对严格筛选的新辅助后影像残留<2 cm的TNBC或HER2+BC患者,可用影像引导VACB评估残留,无残留者或可免手术并放疗,但须在试验框架内进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Response to neoadjuvant systemic therapy (NST) for breast cancer enables tailoring of subsequent therapy. Image-guided breast biopsy after NST can accurately predict a pathologic complete response (pCR). The feasibility phase of the clinical trial reported here assesses omission of breast surgery followed by radiotherapy in terms of local recurrence before trial expansion. STUDY DESIGN: Women with unicentric, cT1-2 N0-1 M0 triple-negative (TNBC) or human epidermal growth factor receptor 2-positive breast cancer (HER2+BC) cancer with <2 cm residual disease on post-NST imaging were eligible to enroll. If no residual invasive or in situ disease was identified by image-guided, vacuum-assisted core biopsy (VACB), breast surgery was omitted, and radiotherapy delivered. The primary endpoint for the feasibility phase was ipsilateral breast tumor recurrence at 6 months. If any recurrence occurred during the feasibility phase the trial would halt. RESULTS: Thirteen patients were enrolled from March 2017 to October 2018. The mean age was 60.8 years (range 51 to 75) and most patients were White (69.2%) and non-Hispanic/Latino (84.6%). All patients had invasive ductal carcinoma (6 TNBC, 7 HER2+BC). Mean tumor size was 2.4 cm (range 0.9 to 5.0) before NST and 0.7 cm (range 0 to 1.8) after NST. Seven patients (53.8%) had residual disease identified on VACB; the remaining 6 (46.2%) comprised the feasibility cohort. At a median follow-up of 44.3 months (range 41.3 to 51.3) there was no ipsilateral breast tumor recurrence in this cohort. CONCLUSIONS: These early data suggest that omission of breast surgery in patients with invasive TNBC and HER2+BC with no evidence of residual disease on standardized VACB after NST is potentially feasible. Results from the expansion phase of this clinical trial will be reported per protocol prespecified analyses.
引用
- Johnson HM, Valero V, Yang WT, et al. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. J Am Coll Surg. 2023. PMID: 36856291. doi:10.1097/XCS.0000000000000670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。